Drug Name Diflucan

Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world.
Birth defects which have been documented following Accutane exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported.

 

Amoxicillin is susceptible to degradation by b-lactamase-producing bacteria, and so may be given with clavulanic acid to decrease its susceptibility.
Dr. Rhee and colleagues compared the identification of prediabetes, dysglycemia (diabetes or prediabetes), and diabetes by the recommended HbA1c-based screening with the conventional oral glucose tolerance test (OGTT).